Palatin Technologies to Present at Cowen Annual Health Care Conference on March 19, 2009
13 Mars 2009 - 12:30PM
PR Newswire (US)
CRANBURY, N.J., March 13 /PRNewswire-FirstCall/ -- Palatin
Technologies, Inc. (NYSE Amex: PTN) today announced that it will
present at the Cowen and Company 29th Annual Health Care Conference
being held at the Boston Marriott Copley Place on Thursday, March
19, 2009 at 11:05 AM. Carl Spana, Ph.D., President and Chief
Executive Officer of Palatin Technologies, will provide an update
on the Company's corporate and development programs. To access the
live audio broadcast or the subsequent archived recording, log onto
http://www.palatin.com/. About Palatin Technologies, Inc. Palatin
Technologies, Inc. is a biopharmaceutical company focused on
discovering and developing targeted, receptor-specific small
molecule and peptide therapeutics. Palatin's strategy is to develop
products and then form marketing collaborations with industry
leaders in order to maximize their commercial potential. For
additional information regarding Palatin, please visit Palatin
Technologies' website at http://www.palatin.com/. Forward-looking
Statements Statements about future expectations of Palatin
Technologies, Inc., including its development programs, proposed
indications for its product candidates, pre-clinical activities,
marketing collaborations, and all other statements in this document
other than historical facts, are "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933,
Section 21E of the Securities Exchange Act of 1934 and as that term
is defined in the Private Securities Litigation Reform Act of 1995.
Palatin intends that such forward-looking statements be subject to
the safe harbors created thereby. Palatin's actual results may
differ materially from those discussed in the forward-looking
statements for various reasons, including, but not limited to
Palatin's ability to fund development of its technology, ability to
establish and successfully complete clinical trials and
pre-clinical studies and the results of those trials and studies,
dependence on its partners for certain development activities, need
for regulatory approvals and commercial acceptance of its products,
ability to protect its intellectual property, and other factors
discussed in the Palatin's periodic filings with the Securities and
Exchange Commission. Palatin is not responsible for updating for
events that occur after the date of this press release. DATASOURCE:
Palatin Technologies, Inc. CONTACT: Investors, Stephen T. Wills,
CPA, MST, EVP-Operations - Chief Financial Officer of Palatin
Technologies, Inc., +1-609-495-2200, , or Media, Susan Kim of Burns
McClellan, +1-212-213-0006, , for Palatin Technologies, Inc. Web
Site: http://www.palatin.com/
Copyright